DOP2005000183A - Procedimiento - Google Patents
ProcedimientoInfo
- Publication number
- DOP2005000183A DOP2005000183A DO2005000183A DO2005000183A DOP2005000183A DO P2005000183 A DOP2005000183 A DO P2005000183A DO 2005000183 A DO2005000183 A DO 2005000183A DO 2005000183 A DO2005000183 A DO 2005000183A DO P2005000183 A DOP2005000183 A DO P2005000183A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- amino
- methylpyridine
- carboxamide
- phenoxy
- trifluoromethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Developing Agents For Electrophotography (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a un procedimiento para preparar 4-{4[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-N-metilpiridin-2 carboxamida y su sal tosilato
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04023131 | 2004-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2005000183A true DOP2005000183A (es) | 2006-03-31 |
Family
ID=35457568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2005000183A DOP2005000183A (es) | 2004-09-29 | 2005-09-23 | Procedimiento |
Country Status (35)
Country | Link |
---|---|
US (1) | US8124782B2 (es) |
EP (1) | EP1797037B1 (es) |
JP (2) | JP2008514657A (es) |
KR (1) | KR101263032B1 (es) |
CN (1) | CN101052619B (es) |
AR (1) | AR053973A1 (es) |
AU (1) | AU2005289099B2 (es) |
BR (1) | BRPI0515944B1 (es) |
CA (1) | CA2581835C (es) |
CU (1) | CU23754B7 (es) |
CY (1) | CY1116126T1 (es) |
DK (1) | DK1797037T3 (es) |
DO (1) | DOP2005000183A (es) |
EC (1) | ECSP077357A (es) |
ES (1) | ES2532377T3 (es) |
GT (1) | GT200500269A (es) |
HK (1) | HK1113484A1 (es) |
HN (1) | HN2005000768A (es) |
HR (1) | HRP20150295T1 (es) |
IL (1) | IL182046A0 (es) |
MA (1) | MA28883B1 (es) |
MY (1) | MY149873A (es) |
NO (1) | NO339647B1 (es) |
NZ (1) | NZ554119A (es) |
PE (5) | PE20060825A1 (es) |
PL (1) | PL1797037T3 (es) |
PT (1) | PT1797037E (es) |
SG (1) | SG155997A1 (es) |
SI (1) | SI1797037T1 (es) |
SV (1) | SV2006002243A (es) |
TW (1) | TWI382973B (es) |
UA (1) | UA90691C2 (es) |
UY (1) | UY29143A1 (es) |
WO (1) | WO2006034796A1 (es) |
ZA (1) | ZA200702511B (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
PT1626714E (pt) | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | Diarilureias para doenças mediadas por pdgfr |
EA010485B1 (ru) | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
CN101052619B (zh) | 2004-09-29 | 2012-02-22 | 拜耳先灵制药股份公司 | 制备4-{4-[({[4-氯-3-(三氟甲基)苯基]氨基}羰基)氨基]苯氧基}-n-甲基吡啶-2-甲酰胺的方法 |
ES2387812T3 (es) | 2004-09-29 | 2012-10-02 | Bayer Pharma Aktiengesellschaft | Forma termodinámicamente estable del tosilato BAY 43-9006 |
KR101335932B1 (ko) | 2005-03-07 | 2013-12-04 | 바이엘 헬스케어 엘엘씨 | 암의 치료를 위한 오메가-카르복시아릴 치환된 디페닐우레아를 포함하는 제약 조성물 |
AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
CA2669158A1 (en) * | 2006-11-14 | 2008-05-22 | Bayer Schering Pharma Aktiengesellschaft | Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
EP2195286A2 (en) * | 2007-09-10 | 2010-06-16 | Cipla Limited | Process for the preparation of a raf kinase inhibitor and intermediates for use in the process |
WO2009054004A2 (en) * | 2007-10-22 | 2009-04-30 | Natco Pharma Limited | Process for the preparation of sorafenib |
EP2231612A1 (en) * | 2008-01-17 | 2010-09-29 | Sicor, Inc. | Polymorph form iii of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof |
US20090253913A1 (en) * | 2008-03-06 | 2009-10-08 | Pierluigi Rossetto | Process for the preparation of sorafenib and salts thereof |
CN103254126A (zh) * | 2008-09-19 | 2013-08-21 | 苏州泽璟生物制药有限公司 | 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物 |
CA2775229C (en) * | 2009-09-24 | 2014-07-29 | Ranbaxy Laboratories Limited | Process for the preparation of sorafenib tosylate |
WO2011036648A1 (en) | 2009-09-24 | 2011-03-31 | Ranbaxy Laboratories Limited | Polymorphs of sorafenib acid addition salts |
EP2499116A1 (en) | 2009-11-12 | 2012-09-19 | Ranbaxy Laboratories Limited | Sorafenib ethylsulfonate salt, process for preparation and use |
WO2011076711A2 (en) | 2009-12-23 | 2011-06-30 | Ratiopharm Gmbh | Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide |
WO2011092663A2 (en) | 2010-01-29 | 2011-08-04 | Ranbaxy Laboratories Limited | 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-n2-methylpyridine-2-carboxamide dimethyl sulphoxide solvate |
CN102190616B (zh) * | 2010-03-18 | 2015-07-29 | 苏州泽璟生物制药有限公司 | 一种氘代的ω-二苯基脲的合成及生产的方法和工艺 |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
CN102617458A (zh) * | 2010-05-18 | 2012-08-01 | 张南 | 抗癌用化合物的制备方法 |
CA2805874A1 (en) | 2010-07-19 | 2012-01-26 | Bayer Healthcare Llc | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
SG189038A1 (en) | 2010-10-01 | 2013-05-31 | Bayer Ip Gmbh | Substituted n-(2-arylamino)aryl sulfonamide-containing combinations |
WO2012071425A1 (en) | 2010-11-22 | 2012-05-31 | Teva Pharmaceutical Industries Ltd. | Solid state forms of sorafenib besylate, and processes for preparations thereof |
EP2559431A1 (en) | 2011-08-17 | 2013-02-20 | Ratiopharm GmbH | Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide |
CN103664771B (zh) * | 2012-09-19 | 2016-03-30 | 齐鲁制药有限公司 | 索拉非尼的晶型a及其制备方法 |
WO2014118807A1 (en) * | 2013-02-04 | 2014-08-07 | Intas Pharmaceuticals Limited | A novel process for the preparation of sorafenib tosylate form iii |
CN104710354A (zh) * | 2013-12-13 | 2015-06-17 | 江苏豪森药业股份有限公司 | 高纯度索拉非尼的制备方法 |
CN104761492A (zh) * | 2014-01-03 | 2015-07-08 | 正大天晴药业集团股份有限公司 | 对甲苯磺酸索拉非尼的晶型及其制备方法 |
CN104177292A (zh) * | 2014-08-08 | 2014-12-03 | 亿腾药业(泰州)有限公司 | 一种工业化生产甲苯磺酸索拉非尼多晶型ⅰ的方法 |
CN110204483B (zh) * | 2014-12-01 | 2021-06-29 | 石药集团中奇制药技术(石家庄)有限公司 | 一种甲苯磺酸索拉非尼新晶型及其制备方法 |
EP3109236B1 (en) | 2015-06-23 | 2017-08-09 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Scalable process for the preparation of sorafenib tosylate ethanol solvate and sorafenib tosylate form iii |
CN105181844A (zh) * | 2015-09-11 | 2015-12-23 | 江苏嘉逸医药有限公司 | 一种高效液相色谱法测定甲苯磺酸索拉非尼含量和有关物质的方法 |
CN105585523A (zh) * | 2015-12-29 | 2016-05-18 | 上海北卡医药技术有限公司 | 一种对甲苯磺酸索拉非尼的新晶型及其制备方法和用途 |
CN107840823B (zh) * | 2016-09-20 | 2021-08-17 | 意大利合成制造有限公司 | 用于制备甲苯磺酸索拉非尼乙醇溶剂化物和iii型甲苯磺酸索拉非尼的可变规模的方法 |
CN107915676A (zh) * | 2017-10-26 | 2018-04-17 | 魏海霞 | 索拉非尼的制备方法 |
CN109796400B (zh) * | 2017-11-16 | 2022-07-29 | 四川科伦药物研究院有限公司 | 一种甲苯磺酸索拉菲尼晶型及其制备方法 |
CN113773249A (zh) * | 2020-06-10 | 2021-12-10 | 杭州中美华东制药有限公司 | 索拉非尼游离碱晶型Form X及其制备方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU86960A1 (fr) * | 1987-07-31 | 1989-03-08 | Oreal | Procede de preparation de piperidino-6 diamino-2,4 pyrimidine oxyde-3 et composes nouveaux |
JPH02934A (ja) * | 1988-05-27 | 1990-01-05 | Konica Corp | 非線形光学材料 |
JP2971291B2 (ja) * | 1993-06-02 | 1999-11-02 | 田辺製薬株式会社 | 光学活性2−アミノ酪酸の製法 |
JP3866323B2 (ja) * | 1996-03-27 | 2007-01-10 | ポーラ化成工業株式会社 | 新規n−ベンジルベンズアミド誘導体 |
JPH09316069A (ja) * | 1996-03-28 | 1997-12-09 | Ajinomoto Co Inc | 新規キサントン誘導体 |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
EE04913B1 (et) * | 1999-01-13 | 2007-10-15 | Bayer Corporation | Omega-karboksarlasendatud difenlkarbamiidid kui RAF-kinaasi inhibiitorid ja neid sisaldavad farmatseutilised kompositsioonid |
GB2367816A (en) * | 2000-10-09 | 2002-04-17 | Bayer Ag | Urea- and thiourea-containing derivatives of beta-amino acids |
ES2275931T5 (es) | 2001-12-03 | 2018-10-23 | Bayer Healthcare Llc | Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos |
US20030207872A1 (en) * | 2002-01-11 | 2003-11-06 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
DE10203086A1 (de) * | 2002-01-28 | 2003-07-31 | Bayer Ag | 5-Ring Heterozyklen |
SI1478358T1 (sl) * | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
KR20050087776A (ko) * | 2002-08-13 | 2005-08-31 | 산도즈 아게 | 세프디니르 중간체 |
ES2294317T3 (es) * | 2002-10-21 | 2008-04-01 | Kirin Pharma Kabushiki Kaisha | Sal de n-(2-cloro-4-((6,7-dimetoxi-4-quinolil)oxi)fenil)-n'-(5-metil-3-isoxazolil)urea de forma cristalina. |
PT1626714E (pt) | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | Diarilureias para doenças mediadas por pdgfr |
CN101052619B (zh) | 2004-09-29 | 2012-02-22 | 拜耳先灵制药股份公司 | 制备4-{4-[({[4-氯-3-(三氟甲基)苯基]氨基}羰基)氨基]苯氧基}-n-甲基吡啶-2-甲酰胺的方法 |
-
2005
- 2005-09-20 CN CN2005800373684A patent/CN101052619B/zh active Active
- 2005-09-20 WO PCT/EP2005/010118 patent/WO2006034796A1/en active Application Filing
- 2005-09-20 ES ES05794785.5T patent/ES2532377T3/es active Active
- 2005-09-20 BR BRPI0515944-0A patent/BRPI0515944B1/pt active IP Right Grant
- 2005-09-20 SI SI200531947T patent/SI1797037T1/sl unknown
- 2005-09-20 PL PL05794785T patent/PL1797037T3/pl unknown
- 2005-09-20 PT PT05794785T patent/PT1797037E/pt unknown
- 2005-09-20 SG SG200906449-4A patent/SG155997A1/en unknown
- 2005-09-20 EP EP05794785.5A patent/EP1797037B1/en active Active
- 2005-09-20 US US11/664,332 patent/US8124782B2/en active Active
- 2005-09-20 KR KR1020077009652A patent/KR101263032B1/ko active IP Right Grant
- 2005-09-20 NZ NZ554119A patent/NZ554119A/en unknown
- 2005-09-20 CA CA2581835A patent/CA2581835C/en active Active
- 2005-09-20 DK DK05794785T patent/DK1797037T3/en active
- 2005-09-20 JP JP2007533904A patent/JP2008514657A/ja active Pending
- 2005-09-20 AU AU2005289099A patent/AU2005289099B2/en active Active
- 2005-09-20 UA UAA200704750A patent/UA90691C2/ru unknown
- 2005-09-23 DO DO2005000183A patent/DOP2005000183A/es unknown
- 2005-09-26 AR ARP050104020A patent/AR053973A1/es active IP Right Grant
- 2005-09-27 MY MYPI20054553A patent/MY149873A/en unknown
- 2005-09-28 PE PE2005001144A patent/PE20060825A1/es active IP Right Grant
- 2005-09-28 PE PE2009000510A patent/PE20091585A1/es active IP Right Grant
- 2005-09-28 PE PE2009000512A patent/PE20091587A1/es active IP Right Grant
- 2005-09-28 PE PE2009000509A patent/PE20091584A1/es active IP Right Grant
- 2005-09-28 PE PE2009000511A patent/PE20091586A1/es not_active Application Discontinuation
- 2005-09-28 UY UY29143A patent/UY29143A1/es active IP Right Grant
- 2005-09-28 TW TW094133620A patent/TWI382973B/zh active
- 2005-09-28 GT GT200500269A patent/GT200500269A/es unknown
- 2005-09-29 SV SV2005002243A patent/SV2006002243A/es active IP Right Grant
- 2005-10-04 HN HN2005000768A patent/HN2005000768A/es unknown
-
2007
- 2007-03-20 IL IL182046A patent/IL182046A0/en active IP Right Grant
- 2007-03-26 CU CU20070069A patent/CU23754B7/es active IP Right Grant
- 2007-03-27 ZA ZA200702511A patent/ZA200702511B/en unknown
- 2007-03-28 EC EC2007007357A patent/ECSP077357A/es unknown
- 2007-03-30 MA MA29788A patent/MA28883B1/fr unknown
- 2007-04-26 NO NO20072173A patent/NO339647B1/no unknown
-
2008
- 2008-04-01 HK HK08103596.4A patent/HK1113484A1/xx unknown
-
2012
- 2012-11-02 JP JP2012242831A patent/JP5583190B2/ja active Active
-
2015
- 2015-03-16 HR HRP20150295TT patent/HRP20150295T1/hr unknown
- 2015-03-17 CY CY20151100268T patent/CY1116126T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2005000183A (es) | Procedimiento | |
ECSP077356A (es) | Forma termodinámicamente estable de una sal tosilato | |
DOP2016000285A (es) | Procedimiento para la preparación de 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridina-2-carboxamida, sus sales y su monohidrato | |
BR112012023525A2 (pt) | método para preparar n-(4-cloro-3(triflúor metil)fenil)-n'-(4-(2-(n-(metil-d3)amino formil)-4-piridiloxi)fenil)uréia, intermediário, método para preparar 4-cloro-piridil-2-(n-(metil-d3))carboxamida, uso do intermediário e composto de ?-difenil uréia deuterada de p-tolueno sulfonato | |
BRPI0516904A (pt) | processo para a preparação de um derivado de 2-etilaminopiridina e composto | |
MX2007007105A (es) | Procedimiento para la preparacion de un derivado de 2-piridiletilcarboxamida. | |
MY142270A (en) | New process for the synthesis of (7-methoxy-1-naphthyl)acetonitrile and application in the synthesis of agomelatine | |
BRPI0509273B8 (pt) | Processo aperfeiçoado para a preparação de n-([1,2,4[triazolpirimidin-2-il)aril sulfonamidas | |
CY1109090T1 (el) | Μεθοδος για την παρασκευη ενωσεων πυραζινης | |
IS7281A (is) | Umbrotsefni (3-{[4-tert-bútýl-bensýl)-(pýridín-3-súlfónýl)-amínó]-metýl}-fenoxý)-ediksýru | |
EA200500204A1 (ru) | Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина | |
TW200735781A (en) | Food product | |
BR0215897B1 (pt) | prepreg e método para sua produção | |
DE602006001889D1 (de) | Vorrichtung und Verfahren zur Codeumsetzung und Aufzeichnungsmedium mit aufgezeichnetem Programm für einen Computer zur Ausführung des Verfahrens | |
AR055007A1 (es) | Proceso de fabricacion de salicilamidas n-sustituidas | |
AR051933A1 (es) | Proceso para la preparacion de n-(3,5 dicloropirid-4-ilo)-4-difluormetoxi-8-metano sulfonamido-dibenzo[b,d] furano-1-carboxamida | |
DOP2005000184A (es) | Forma termodinamicamente estable de una sal tosilato | |
RS51494B (en) | THE USE OF AGOMELATIN FOR OBTAINING MEDICINES FOR THE TREATMENT OF PERIVENTRICULAR LEUKOMALATION | |
EA200801142A1 (ru) | Способ получения амидов и сложных эфиров пиридинкарбоновой кислоты | |
ITMI20040679A1 (it) | Composto con attivita' vitaminica k particolarmente come additivo per mangimi e sua preparazione | |
IL183529A0 (en) | Tri(hydroxymethyl)methylamine salt or an ethanol amine salt of (2s)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid |